Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Therapeutics Inc.

Kepler Capital analyst Laurent Daure maintained a Buy rating on Capgemini SE on December 10 and set a price target of €195.00. The company’s shares...

Capgemini SE (0HAZ): New Buy Recommendation for This Technology Giant

Cullinan Management ( ($CGEM) ) has issued an announcement. On December 8, 2025, Cullinan Therapeutics presented updated clinical data from its Pha...

Cullinan Therapeutics Presents Promising CLN-049 Data

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Cullinan Management, with a price target of $38.00. According ...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CGEM	$11.92	-3.72%	955.51K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CGEM	$11.92	-3.7%	955.51K
3
4
5
6

CGEM

CGEM

Dividend Overview

Get Cullinan Therapeutics Inc. Data in Excel

Get Cullinan Therapeutics Inc. Data in Excel